28Nov 2024
Rutin Emerges as Key Inhibitor for SARS-CoV-2 Protease

Rutin Emerges as Key Inhibitor for SARS-CoV-2 Protease

Despite the reduced intensity of the COVID-19 pandemic, SARS-CoV-2 continues to circulate, necessitating the development of treatments targeting viral mutations. This study evaluated Peruvian natural compounds against various SARS-CoV-2 main protease (Mpro) mutations using in silico approaches, including virtual screening, molecular dynamics simulations, and energy estimation analyses. Rutin was identified as the top candidate, demonstrating strong binding affinity and high structural and energetic stability with different Mpro mutations. These findings suggest that rutin could serve as a foundational compound for designing treatments against emerging SARS-CoV-2 variants, highlighting its potential in antiviral drug development.

  • #general medicine

Like

Save

Share